NYX‐458 improves cognitive performance in a primate Parkinson's disease model
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NYX‐458 improves cognitive performance in a primate Parkinson's disease model
Authors
Keywords
-
Journal
MOVEMENT DISORDERS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-01-22
DOI
10.1002/mds.27962
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NYX-2925 is a novel NMDA receptor modulator that induces rapid and long-lasting analgesia in rat models of neuropathic pain
- (2018) Nayereh Ghoreishi-Haack et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory
- (2017) M Amin Khan et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Epidemiology of Parkinson’s disease
- (2017) Ole-Bjørn Tysnes et al. JOURNAL OF NEURAL TRANSMISSION
- A new tool to identify patients with Parkinson's disease at increased risk of dementia
- (2017) Dag Aarsland et al. LANCET NEUROLOGY
- The neural basis of reversal learning: An updated perspective
- (2017) A. Izquierdo et al. NEUROSCIENCE
- Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains
- (2015) Michael R Weed et al. NEUROPSYCHOPHARMACOLOGY
- Dissociable effects of NR2A and NR2B NMDA receptor antagonism on cognitive flexibility but not pattern separation
- (2015) Gaurav Kumar et al. PSYCHOPHARMACOLOGY
- TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque
- (2013) Tom H. Johnston et al. NEUROPHARMACOLOGY
- Levodopa improves motor deficits but can further disrupt cognition in a macaque parkinson model
- (2012) Jay S. Schneider et al. MOVEMENT DISORDERS
- A critique of available scales and presentation of the non-human primate dyskinesia rating scale
- (2012) Susan H. Fox et al. MOVEMENT DISORDERS
- l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease
- (2012) Philippe Huot et al. NEUROPHARMACOLOGY
- Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias
- (2011) Imtiaz Ahmed et al. BRAIN
- MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI
- (2011) Irene Litvan et al. MOVEMENT DISORDERS
- Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease
- (2010) T. H. Johnston et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Two Mechanisms for Task Switching in the Prefrontal Cortex
- (2009) A. Hyafil et al. JOURNAL OF NEUROSCIENCE
- Randomized controlled trial of memantine in dementia associated with Parkinson's disease
- (2009) Iracema Leroi et al. MOVEMENT DISORDERS
- Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease
- (2009) Angie A. Kehagia et al. NEUROPSYCHOLOGIA
- Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism
- (2008) John G. Nutt et al. MOVEMENT DISORDERS
- The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
- (2008) Mariese A. Hely et al. MOVEMENT DISORDERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search